Immunic, Inc. (NASDAQ:IMUX) Expected to Post Earnings of -$0.72 Per Share

Equities analysts forecast that Immunic, Inc. (NASDAQ:IMUX – Get Rating) will announce earnings per share (EPS) of ($0.72) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Immunic’s earnings, with estimates ranging from ($0.93) to ($0.62). Immunic reported earnings of ($0.82) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 12.2%. The firm is scheduled to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Immunic will report full year earnings of ($3.01) per share for the current year, with EPS estimates ranging from ($3.76) to ($2.65). For the next year, analysts forecast that the firm will report earnings of ($3.30) per share, with EPS estimates ranging from ($4.67) to ($2.83). Zacks’ earnings per share averages are a mean average based on a survey of analysts that cover Immunic.

Immunic (NASDAQ:IMUX – Get Rating) last issued its quarterly earnings results on Thursday, February 24th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.08). During the same period last year, the firm posted ($0.46) EPS.

IMUX has been the topic of several recent analyst reports. Wedbush restated an “outperform” rating on shares of Immunic in a research report on Friday, May 6th. Zacks Investment Research downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research report on Tuesday, May 3rd. StockNews.com initiated coverage on shares of Immunic in a research report on Thursday, March 31st. They set a “sell” rating on the stock. Finally, Piper Sandler decreased their price objective on shares of Immunic from $71.00 to $39.00 and set an “overweight” rating on the stock in a research report on Tuesday. Two research analysts have rated the stock with a sell rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $34.50.

Shares of Immunic stock traded up $0.29 on Friday, hitting $5.77. 279,872 shares of the company’s stock were exchanged, compared to its average volume of 286,239. The company has a 50-day simple moving average of $9.08 and a 200-day simple moving average of $10.06. The stock has a market capitalization of $176.22 million, a PE ratio of -1.84 and a beta of 1.99. Immunic has a 1 year low of $4.96 and a 1 year high of $15.12.

In other Immunic news, Chairman Duane Nash bought 10,000 shares of Immunic stock in a transaction dated Thursday, May 12th. The shares were purchased at an average cost of $5.03 per share, for a total transaction of $50,300.00. Following the acquisition, the chairman now directly owns 22,032 shares in the company, valued at approximately $110,820.96. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last 90 days, insiders bought 20,000 shares of company stock worth $101,240. Insiders own 12.07% of the company’s stock.

Large investors have recently modified their holdings of the stock. Schonfeld Strategic Advisors LLC grew its holdings in Immunic by 6.9% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 54,400 shares of the company’s stock valued at $482,000 after purchasing an additional 3,500 shares during the last quarter. Altium Capital Management LP bought a new position in Immunic during the 3rd quarter valued at about $320,000. Geode Capital Management LLC grew its holdings in Immunic by 21.4% during the 3rd quarter. Geode Capital Management LLC now owns 313,953 shares of the company’s stock valued at $2,778,000 after purchasing an additional 55,384 shares during the last quarter. Parkman Healthcare Partners LLC grew its holdings in Immunic by 123.2% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 924,087 shares of the company’s stock valued at $8,178,000 after purchasing an additional 510,000 shares during the last quarter. Finally, Deutsche Bank AG grew its holdings in Immunic by 16.9% during the 3rd quarter. Deutsche Bank AG now owns 10,768 shares of the company’s stock valued at $95,000 after purchasing an additional 1,559 shares during the last quarter. Institutional investors own 49.03% of the company’s stock.

Immunic Company Profile (Get Rating)

Immunic, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease.

See Also